Cellevate Secures SEK 21.3 Million Financing to Advance Commercialization

LUND, Sweden – March 30, 2026 – Cellevate AB today announced the successful closing of a new financing round in February 2026, raising SEK 21.3 million from a combination of existing shareholders and new investors, including Almi Invest.

The strong participation from both current and new investors reflects continued confidence in Cellevate’s strategy, execution capabilities, and long-term value creation potential. The Board of Directors and management view this support as a clear validation of the company’s direction and its progress in advancing Cellevat3d® VAX nanofibers commercialization and scale up together with strategic partners and vaccine producers.

For more information, please contact:

Karsten Fjärstedt

Interim CEO, Cellevate

Email: karsten.fjarstedt@cellevate.com

About Cellevate

Cellevate is a Swedish biotech company based on proprietary nanofiber technology dedicated to building the next generation cell culture solutions for cell and gene therapy and novel vaccines biomanufacturing. The company is ISO 9001:2015 certified and has implemented GMP processes for production in clean room. The core nanotechnology, Cellevat3d® is a sustainable, deeptech innovation for the biopharmaceutical industry. This platform allows industrial-scale production of a new category of nanofiber cell culture systems – with unparalleled surface area for cell growth, reproducibility, customization, and scalability, which ultimately lead to increased yield, productivity and process economy. Cellevat3d® nanofiber-based products are designed and validated as an integrated part of upstream bioprocessing solutions, from laboratory to large-scale production.

For more information, please visit www.cellevate.com.

About Almi Invest

Almi Invest is Sweden’s most active startup investor and a state-owned, industry-independent venture capital company, with a substantial part of the portfolio within life science.